Episode 8: The Gatekeeper Who Is Leaving the Building

The traditional Indian pharma commercial model was built around one assumption: that the physician is the primary, often the only, gatekeeper between a molecule and a patient, and that an army of medical representatives visiting doctors’ clinics is the most effective way to influence that gatekeeper. That assumption is now wrong for a rapidly growing share of the market, across all three income tiers of the country simultaneously, for three different and unrelated reasons. The three-India framework from earlier analytical work is the right lens for seeing this clearly because the disintermediation is happening differently, and at different speeds, in each of the three Indias.• The three-India commercial reality, updated with new 2025-2026 data showing which segment is being disintermediated by what, and how fast• Government digital health infrastructure at unprecedented scale - 780 million ABHA digital health IDs, 372 million eSanjeevani teleconsultations, numbers most pharma commercial strategy decks have not internalised• The quick-commerce entry into pharmacy (Zepto Pharmacy’s 10-minute delivery) as a genuinely new disruptive vector • Tata 1mg and PharmEasy’s combined 55% share of online pharmacy sales, non-pharma-company platforms now sitting at the centre of the distribution chain• What this means concretely for how Indian pharma should restructure commercial spend, threading back to the Episode 7 capital allocation lensListen in to Episode 8 of the Bio-Health Supercycle.“My Pharma Reviews - The Podcast” is now available for you to listen on your favourite podcasting apps like Spotify and Apple. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com